More and more states are mirroring federal policies on drugs. States have expanded their sights to regulate PBMs, drug access, and drug manufacturers.
2024 promises to bring even more efforts by states to regulate drugs and drug prices, but questions remain.
How far can states go legally? How big is this market? What part of health care is next for government price controls? Is this a party-line issue?
To answer those questions, HGA hosted a webinar with panelists J.P. Wieske from Horizon Government Affairs and Andrew Barnhill from IQVIA. The two discussed:
- Rising popularity of State Prescription Drug Affordability Boards (PDABs) and their impact on drug prices
- How to evaluate what’s really going on with drug pricing
- Impact of AI on the cost of developing new prescription drugs
- State efforts to lower out-of-pocket costs for rare disease patients through Medicaid pharmacy outcomes-based arrangements
- Prescription drug shortages